The current understanding of heart failure (HF) does not fully explain the spectrum of HF
symptoms. Most HF hospitalizations are related to sodium (Na+) and fluid retention resulting …

Background Concerns for hyperkalaemia limit the use of mineralocorticoid receptor
antagonists (MRAs). The frequency of MRA‐associated hyperkalaemia in real‐world …

Randomized controlled trials have demonstrated the benefits of guideline-directed medical
therapy in the outpatient setting for treatment of chronic heart failure. However, the benefits …

Although therapy with mineralocorticoid receptor antagonists (MRAs) is recommended for
patients with chronic heart failure (HF) with reduced ejection fraction and in post-infarction …

Introduction: Hyperkalemia is a common electrolyte disorder, especially among patients with
chronic kidney disease (CKD), diabetes mellitus, or heart failure, and is associated with a …

Background—Heart failure guidelines recommend routine monitoring of serum potassium,
and renal function in patients treated with a mineralocorticoid receptor antagonist (MRA) …

Despite recent advances in the treatment of chronic heart failure, therapeutic options for
acute heart failure (AHF) remain limited. AHF admissions are associated with significant …

Background Mineralocorticoid receptor antagonists (MRA) are an underutilized therapy for
heart failure with a reduced ejection fraction (HFrEF), but the current impact of …

Numerous registries, including the most recent ESC Euro-observational registry, have
reported a large and persistent gap between real-life practice in the use of life-saving …

Background Despite concerns about mineralocorticoid receptor antagonist therapies
(MRAs) underuse and misuse in patients with heart failure, temporal and institutional …